Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adocia prepares for Phase III of diabetic foot ulcer treatment

This article was originally published in Scrip

Executive Summary

French biotechnology company Adocia has said it is actively preparing for Phase III trials of its diabetic foot ulcer treatment, BioChaperone combined with PDGF-BB (platelet-derived growth factor BB), for the second half of 2013 in the US and Europe. Simultaneously, it is planning to begin a Phase III trial in India in the fourth quarter of 2012, with a view to registering the drug in emerging countries in late 2014.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC017111

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel